JP2011523633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523633A5 JP2011523633A5 JP2011508655A JP2011508655A JP2011523633A5 JP 2011523633 A5 JP2011523633 A5 JP 2011523633A5 JP 2011508655 A JP2011508655 A JP 2011508655A JP 2011508655 A JP2011508655 A JP 2011508655A JP 2011523633 A5 JP2011523633 A5 JP 2011523633A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- chlorobenzenesulfonyl
- phenyl
- acetamide
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 difluorophenylmethylphenyl Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005059 halophenyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VWYVTSWONLHSTA-XMMPIXPASA-N (2r)-2-[(4-chlorophenyl)sulfonyl-[(2-ethyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]amino]-2-phenylacetamide Chemical compound C1([C@H](C(N)=O)N(CC=2C=C3CCN(C(C3=CC=2)=O)CC)S(=O)(=O)C=2C=CC(Cl)=CC=2)=CC=CC=C1 VWYVTSWONLHSTA-XMMPIXPASA-N 0.000 claims 1
- SOTSONPVQTXFNM-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-(pyridin-4-ylmethyl)amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=NC=C1 SOTSONPVQTXFNM-UHFFFAOYSA-N 0.000 claims 1
- HBJJHQQBEKHWRK-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[(2-ethyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C=C2C(=O)N(CC)CCC2=CC=1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC(F)=CC(F)=C1 HBJJHQQBEKHWRK-UHFFFAOYSA-N 0.000 claims 1
- OFNSEVGBKLQWGK-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[(4-cyanophenyl)methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C#N)C=C1 OFNSEVGBKLQWGK-UHFFFAOYSA-N 0.000 claims 1
- AWISVPJARYEHMZ-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[(4-cyanophenyl)methyl]amino]-2-[2-(trifluoromethyl)phenyl]acetamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C#N)C=C1 AWISVPJARYEHMZ-UHFFFAOYSA-N 0.000 claims 1
- FSPXKUNSSIVVEV-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[(4-fluorophenyl)methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(F)C=C1 FSPXKUNSSIVVEV-UHFFFAOYSA-N 0.000 claims 1
- DMYIVLYREILNDD-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[[4-(1,3-oxazol-2-yl)phenyl]methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC(C=C1)=CC=C1C1=NC=CO1 DMYIVLYREILNDD-UHFFFAOYSA-N 0.000 claims 1
- GYTJLHQCAXWYRA-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[[4-(1H-pyrazol-5-yl)phenyl]methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC(C=C1)=CC=C1C=1C=CNN=1 GYTJLHQCAXWYRA-UHFFFAOYSA-N 0.000 claims 1
- HJWHLUQKQBSYHF-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[[4-(1h-1,2,4-triazol-5-yl)phenyl]methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC(C=C1)=CC=C1C=1N=CNN=1 HJWHLUQKQBSYHF-UHFFFAOYSA-N 0.000 claims 1
- LPHQZJDRCANHKP-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[[4-(1h-imidazol-2-yl)phenyl]methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC(C=C1)=CC=C1C1=NC=CN1 LPHQZJDRCANHKP-UHFFFAOYSA-N 0.000 claims 1
- STHFUVYIMVZRJH-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[[4-(trifluoromethyl)phenyl]methyl]amino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C(F)(F)F)C=C1 STHFUVYIMVZRJH-UHFFFAOYSA-N 0.000 claims 1
- PYHNZTFVPGTBSI-UHFFFAOYSA-N 2-[[4-(azetidine-1-carbonyl)phenyl]methyl-(4-chlorophenyl)sulfonylamino]-2-(3,5-difluorophenyl)acetamide Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC(C=C1)=CC=C1C(=O)N1CCC1 PYHNZTFVPGTBSI-UHFFFAOYSA-N 0.000 claims 1
- QGCSBLREEATEDO-UHFFFAOYSA-N 4-[[[2-amino-1-(2,4-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC=C(F)C=C1F QGCSBLREEATEDO-UHFFFAOYSA-N 0.000 claims 1
- LQCYWMGNIKBKNS-UHFFFAOYSA-N 4-[[[2-amino-1-(2,4-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC=C(F)C=C1F LQCYWMGNIKBKNS-UHFFFAOYSA-N 0.000 claims 1
- FFDTVDXXSYZKIN-UHFFFAOYSA-N 4-[[[2-amino-1-(2,4-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]benzoic acid Chemical compound C=1C=C(F)C=C(F)C=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C(O)=O)C=C1 FFDTVDXXSYZKIN-UHFFFAOYSA-N 0.000 claims 1
- SKKVIVLGDOIDKD-UHFFFAOYSA-N 4-[[[2-amino-1-(3,5-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC(F)=CC(F)=C1 SKKVIVLGDOIDKD-UHFFFAOYSA-N 0.000 claims 1
- IZKBVYJYDMAWOO-UHFFFAOYSA-N 4-[[[2-amino-1-(3,5-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC(F)=CC(F)=C1 IZKBVYJYDMAWOO-UHFFFAOYSA-N 0.000 claims 1
- QRYIQYCRZBIHBS-UHFFFAOYSA-N 4-[[[2-amino-1-(3,5-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC(F)=CC(F)=C1 QRYIQYCRZBIHBS-UHFFFAOYSA-N 0.000 claims 1
- OUZXJQAYQZZSHA-UHFFFAOYSA-N 4-[[[2-amino-1-(3,5-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]benzoic acid Chemical compound C=1C(F)=CC(F)=CC=1C(C(=O)N)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C(O)=O)C=C1 OUZXJQAYQZZSHA-UHFFFAOYSA-N 0.000 claims 1
- ZWUSEBNQXBTVSA-UHFFFAOYSA-N 4-[[[2-amino-1-(4-methoxyphenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC=C(OC)C=C1 ZWUSEBNQXBTVSA-UHFFFAOYSA-N 0.000 claims 1
- BFPFWKKTFKCTRY-UHFFFAOYSA-N 4-[[[2-amino-1-(4-methoxyphenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(C(N)=O)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C(O)=O)C=C1 BFPFWKKTFKCTRY-UHFFFAOYSA-N 0.000 claims 1
- YAWITYMVEMMNRI-UHFFFAOYSA-N 4-[[[2-amino-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-(4-chlorophenyl)sulfonylamino]methyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC=CC=C1C(F)(F)F YAWITYMVEMMNRI-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- PDGUMEDNPFCRKG-UHFFFAOYSA-N tert-butyl 4-[[[2-amino-1-(2,4-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC=C(F)C=C1F PDGUMEDNPFCRKG-UHFFFAOYSA-N 0.000 claims 1
- RLSKRIJKXDOAII-UHFFFAOYSA-N tert-butyl 4-[[[2-amino-1-(3,5-difluorophenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN(S(=O)(=O)C=1C=CC(Cl)=CC=1)C(C(N)=O)C1=CC(F)=CC(F)=C1 RLSKRIJKXDOAII-UHFFFAOYSA-N 0.000 claims 1
- YPEYPRXQRGZOPM-UHFFFAOYSA-N tert-butyl 4-[[[2-amino-1-(4-methoxyphenyl)-2-oxoethyl]-(4-chlorophenyl)sulfonylamino]methyl]benzoate Chemical compound C1=CC(OC)=CC=C1C(C(N)=O)N(S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1=CC=C(C(=O)OC(C)(C)C)C=C1 YPEYPRXQRGZOPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5141308P | 2008-05-08 | 2008-05-08 | |
| US61/051,413 | 2008-05-08 | ||
| PCT/US2009/043116 WO2009137657A1 (en) | 2008-05-08 | 2009-05-07 | 2-aryl glycinamide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011523633A JP2011523633A (ja) | 2011-08-18 |
| JP2011523633A5 true JP2011523633A5 (https=) | 2012-06-07 |
Family
ID=41264997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508655A Pending JP2011523633A (ja) | 2008-05-08 | 2009-05-07 | ２−アリールグリシンアミド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110059940A1 (https=) |
| EP (1) | EP2278878A4 (https=) |
| JP (1) | JP2011523633A (https=) |
| CN (1) | CN102088855A (https=) |
| WO (1) | WO2009137657A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1289469C (zh) | 2001-12-20 | 2006-12-13 | 布里斯托尔-迈尔斯斯奎布公司 | α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US20110071199A1 (en) * | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| JPWO2011007819A1 (ja) * | 2009-07-17 | 2012-12-27 | 塩野義製薬株式会社 | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 |
| WO2012047926A2 (en) * | 2010-10-04 | 2012-04-12 | The Brigham And Women's Hospital, Inc. | Sulfonamide-containing compounds |
| EP2928471B1 (en) | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| CN112939895B (zh) * | 2021-02-08 | 2022-11-04 | 桂林医学院 | 一种甘氨酰胺类衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) * | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) * | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| IL123901A (en) * | 1995-11-17 | 2003-06-24 | Warner Lambert Co | Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them |
| US6313123B1 (en) * | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| WO2000050391A1 (en) * | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| CN1289469C (zh) * | 2001-12-20 | 2006-12-13 | 布里斯托尔-迈尔斯斯奎布公司 | α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂 |
| BRPI0408962A (pt) * | 2003-03-31 | 2006-04-04 | Wyeth Corp | inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados |
| US8193389B2 (en) * | 2004-03-11 | 2012-06-05 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| US7163942B2 (en) * | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| US7144894B2 (en) * | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| US7838550B2 (en) * | 2006-02-17 | 2010-11-23 | Wyeth Llc | Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols |
| PE20080169A1 (es) * | 2006-02-17 | 2008-04-11 | Wyeth Corp | Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
-
2009
- 2009-05-07 CN CN2009801278191A patent/CN102088855A/zh active Pending
- 2009-05-07 WO PCT/US2009/043116 patent/WO2009137657A1/en not_active Ceased
- 2009-05-07 US US12/990,922 patent/US20110059940A1/en not_active Abandoned
- 2009-05-07 JP JP2011508655A patent/JP2011523633A/ja active Pending
- 2009-05-07 EP EP09743643.0A patent/EP2278878A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523633A5 (https=) | ||
| ES2532357T3 (es) | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor | |
| US9763957B2 (en) | Autotaxin inhibitors | |
| ES2791340T3 (es) | Derivado de urea o sal farmacológicamente aceptable del mismo | |
| ES2379076T3 (es) | Derivados de pirazol útiles como inhibidores de COX-I | |
| JP6162230B2 (ja) | ネプリライシン阻害剤 | |
| JP2013519680A5 (https=) | ||
| JP2008513500A5 (https=) | ||
| JP2007511485A5 (https=) | ||
| SI20208A (sl) | INHIBITORJI FAKTORJA Xa Z NEVTRALNO P1 SPECIFIČNO SKUPINO | |
| JP2008201787A5 (https=) | ||
| ES2624291T3 (es) | Inhibidores cíclicos del enlace éter de DGAT1 | |
| JP2006504658A5 (https=) | ||
| JP2012528847A5 (https=) | ||
| JP2011515462A5 (https=) | ||
| WO2009055721A3 (en) | 5-lipoxygenase activating protein (flap) inhibitor | |
| JP2009538333A5 (https=) | ||
| JP2013517283A5 (https=) | ||
| JP2008517926A5 (https=) | ||
| TW201038586A (en) | Sulfonamide derivatives | |
| JP2014511869A5 (https=) | ||
| JP2010504280A5 (https=) | ||
| JP2010533158A5 (https=) | ||
| WO2005087729A1 (en) | 5-hydroxyindole-3-carboxylates derivatives and their use | |
| JP2012530705A5 (https=) |